A loss-of-function genetic screening reveals synergistic targeting of AKT/mTOR and WTN/β-catenin pathways for treatment of AML with high PRL-3 phosphatase

BACKGROUND: Protein tyrosine phosphatase of regenerating liver 3 (PRL-3) is overexpressed in a subset of AML patients with inferior prognosis, representing an attractive therapeutic target. However, due to relatively shallow pocket of the catalytic site of PRL-3, it is difficult to develop selective...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Jianbiao, Toh, Sabrina Hui-Min, Chan, Zit-Liang, Quah, Jessie Yiying, Chooi, Jing-Yuan, Tan, Tuan Zea, Chong, Phyllis S. Y., Zeng, Qi, Chng, Wee-Joo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5842526/
https://www.ncbi.nlm.nih.gov/pubmed/29514683
http://dx.doi.org/10.1186/s13045-018-0581-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5842526/
https://www.ncbi.nlm.nih.gov/pubmed/29514683
http://dx.doi.org/10.1186/s13045-018-0581-9

Ejemplares similares